Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 3
2014 6
2015 11
2016 26
2017 42
2018 56
2019 92
2020 143
2021 206
2022 254
2023 256
2024 265
2025 157

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,379 results

Results by year

Filters applied: . Clear all
Page 1
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L, Li Y, Tan J, Xu L, Li Y. Cai L, et al. J Hematol Oncol. 2023 Sep 5;16(1):101. doi: 10.1186/s13045-023-01499-1. J Hematol Oncol. 2023. PMID: 37670328 Free PMC article. Review.
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with …
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surger …
TIGIT in cancer immunotherapy.
Chauvin JM, Zarour HM. Chauvin JM, et al. J Immunother Cancer. 2020 Sep;8(2):e000957. doi: 10.1136/jitc-2020-000957. J Immunother Cancer. 2020. PMID: 32900861 Free PMC article. Review.
Specifically, T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a promising new target for cancer immunotherapy. TIGIT is upregulated by immune cells, including activated T cells, natural killer cells, and regulatory T cells. ...These findi …
Specifically, T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a promising new target for cancer immunothe …
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X, Tian W, Wang Z, Zhang J, Zhou R. Chu X, et al. Mol Cancer. 2023 Jun 8;22(1):93. doi: 10.1186/s12943-023-01800-3. Mol Cancer. 2023. PMID: 37291608 Free PMC article. Review.
Several clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition in various cancer types, and the results are awaited. ...Overall, co-inhibition of TIGIT and PD-1/PD-L1 represents a promising therapeutic approach …
Several clinical trials are underway to evaluate the safety and efficacy of TIGIT and PD-1/PD-L1 co-inhibition in various cancer …
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
Chiang EY, Mellman I. Chiang EY, et al. J Immunother Cancer. 2022 Apr;10(4):e004711. doi: 10.1136/jitc-2022-004711. J Immunother Cancer. 2022. PMID: 35379739 Free PMC article. Review.
One such immune checkpoint axis is comprised of members of the PVR/nectin family that includes the inhibitory receptor T cell immunoreceptor with Ig and immunoreceptor tyrosine-based inhibitory domains (TIGIT). Interestingly, TIGIT acts to regulate the activity of a …
One such immune checkpoint axis is comprised of members of the PVR/nectin family that includes the inhibitory receptor T cell immunoreceptor …
TIGIT as an emerging immune checkpoint.
Harjunpää H, Guillerey C. Harjunpää H, et al. Clin Exp Immunol. 2020 May;200(2):108-119. doi: 10.1111/cei.13407. Epub 2019 Dec 25. Clin Exp Immunol. 2020. PMID: 31828774 Free PMC article. Review.
TIGIT has emerged as a key inhibitor of anti-tumour responses that can hinder multiple steps of the cancer immunity cycle. Pre-clinical studies indicated that TIGIT blockade may protect against various solid and haematological cancers. Several monoclon …
TIGIT has emerged as a key inhibitor of anti-tumour responses that can hinder multiple steps of the cancer immunity cycle. Pre …
Combining TIGIT Blockade with MDSC Inhibition Hinders Breast Cancer Bone Metastasis by Activating Antitumor Immunity.
Monteran L, Ershaid N, Scharff Y, Zoabi Y, Sanalla T, Ding Y, Pavlovsky A, Zait Y, Langer M, Caller T, Eldar-Boock A, Avivi C, Sonnenblick A, Satchi-Fainaro R, Barshack I, Shomron N, Zhang XH, Erez N. Monteran L, et al. Cancer Discov. 2024 Jul 1;14(7):1252-1275. doi: 10.1158/2159-8290.CD-23-0762. Cancer Discov. 2024. PMID: 38427556
Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. ...Specifically, we identified the PD-1 and TIGIT signaling axes and the proinflammatory cytokine IL1beta as central players in the intera …
Bone is the most common site of breast cancer metastasis. Bone metastasis is incurable and is associated with severe morbidity. ...Sp …
Single-Cell RNA Sequencing Reveals the Tissue Architecture in Human High-Grade Serous Ovarian Cancer.
Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, Cen Y, Fei W, Zhang B, Shen Y, Lu W. Xu J, et al. Clin Cancer Res. 2022 Aug 15;28(16):3590-3602. doi: 10.1158/1078-0432.CCR-22-0296. Clin Cancer Res. 2022. PMID: 35675036 Free PMC article.
In addition, an immune coinhibitory receptor TIGIT was highly expressed on CD8+ TEX cells and TIGIT blockade could significantly reduce ovarian cancer tumor growth in mouse models. ...The major applications of our findings are a four-EMT gene model for predic …
In addition, an immune coinhibitory receptor TIGIT was highly expressed on CD8+ TEX cells and TIGIT blockade could significant …
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. Ge Z, et al. Front Immunol. 2021 Jul 22;12:699895. doi: 10.3389/fimmu.2021.699895. eCollection 2021. Front Immunol. 2021. PMID: 34367161 Free PMC article. Review.
Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. The first interim results show promise for combined TIGIT and PD-L1 co-blockade in solid cancer patients. In this review, we summar …
Numerous clinical trials on TIGIT-blockade in cancer have recently been initiated, predominantly combination treatments. The f …
CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy.
Mu Y, Guan X. Mu Y, et al. Curr Med Chem. 2024;31(13):1634-1645. doi: 10.2174/0929867330666230324152532. Curr Med Chem. 2024. PMID: 38666504 Review.
Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing r …
Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin an …
Clinical Development of Anti-TIGIT Antibodies for Immunotherapy of Cancer.
Florou V, Garrido-Laguna I. Florou V, et al. Curr Oncol Rep. 2022 Sep;24(9):1107-1112. doi: 10.1007/s11912-022-01281-5. Epub 2022 Apr 12. Curr Oncol Rep. 2022. PMID: 35412226 Review.
PURPOSE OF REVIEW: T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies under exploration in cancer therapy. Here, we review the available data from the early trials and overview upcoming clinical trials on …
PURPOSE OF REVIEW: T-cell immunoglobulin and ITIM domain (TIGIT) is a next-generation inhibitory receptor with multiple antibodies un …
1,379 results